Pratley Richard E
University of Vermont College of Medicine, Diabetes and Metabolism Translational Medicine Unit, Colchester Research Facility 110C, 208 Park Street, Colchester, VT 05446, USA.
Expert Opin Pharmacother. 2009 Feb;10(3):503-12. doi: 10.1517/14656560802694713.
Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes.
To provide an overview of the mechanism by which alogliptin reduces hyperglycemia and to summarize the pharmacology, efficacy and safety of the drug.
A Medline search was conducted and abstracts and presentations from recent American Diabetes Association and European Association for the Study of Diabetes (EASD) meetings were reviewed. The results of Phase II and Phase III human studies were evaluated for clinical efficacy, safety and tolerability in patients with type 2 diabetes.
RESULTS/CONCLUSIONS: Alogliptin is effective as a treatment for type 2 diabetes, either as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas and insulin. It is well tolerated and has an excellent safety profile. Additional studies are needed to evaluate the long-term safety and efficacy of alogliptin.
阿格列汀是一种强效、高选择性二肽基肽酶-4抑制剂，目前正在进行临床试验，以支持其用于治疗2型糖尿病的新药申请。
概述阿格列汀降低高血糖的机制，并总结该药物的药理学、疗效和安全性。
进行了Medline检索，并查阅了美国糖尿病协会和欧洲糖尿病研究协会（EASD）近期会议的摘要和报告。评估了II期和III期人体研究在2型糖尿病患者中的临床疗效、安全性和耐受性结果。
结果/结论：阿格列汀作为单药治疗或与二甲双胍、噻唑烷二酮类、磺脲类和胰岛素联合使用时，对2型糖尿病有效。它耐受性良好，安全性极佳。需要进一步研究以评估阿格列汀的长期安全性和疗效。
